




**Figure 1: Impact of Coverage Depth on VAF Overlap**



With only 100x coverage (panel A), there is considerable overlap between 5% and 1% VAF, inhibiting the ability to confidently call low-frequency variants below 5%. In contrast, variants below 5% frequency can be reliably called when coverage depth is increased to > 500x coverage (panel B).

### Superior Signal Resolution

For simplicity, and to be conservative, the somatic variant caller only considers two alleles or variant states: reference and variant. Any other calls are considered reference calls. For example, A/C/G/T counts of 100/10/1/1 for reference A are considered to be K = 10 variants out of N = 112 coverage. Under the null hypothesis, it is assumed that no variant is present and that any non-reference calls are due to noise. Given a Q20 base filter, the acceptable noise level is 1%. For simplicity, it is assumed that the expected number of non-reference calls due to noise should follow a Poisson distribution with a mean of  $\lambda = 0.01 * N$ . The equation  $P = 1 - \text{CDF}(K - 1, \lambda)$  represents the probability (P) of having K or more variant calls, where CDF is the cumulative distribution function of the Poisson distribution. P is the probability that no variant is present, given K or more observations. In this way, P is the theoretical false-positive rate, and this probability is converted to a Q score with the maximum Q score set to 100. As seen in Figure 1, greater depth of coverage yields greater discrimination of signal from noise.

### High Reproducibility

The somatic variant caller delivers a high level of reproducibility in detecting variants within cancer samples. In a study comparing MiSeq versus Sanger sequencing, the somatic variant caller results for KRAS and BRAF mutations were within 5% of that reported by Sanger sequencing (Table 2). These results highlight the reproducibility and reliability of the TSACP and MiSeq system for detection of somatic mutations.

### Somatic Variant Caller Data Analysis

The new somatic variant reporter tool (Figure 2) is built into the MiSeq Reporter v1.3+ software, and is available in BaseSpace. Its output is a .VCF file that contains the identified SNPs and associated Q scores.

Researchers who have legacy cancer samples analyzed with a prior version of MiSeq Reporter may re-queue their legacy data for analysis

illumina • 1.800.809.4566 toll-free (U.S.) • +1.858.202.4566 tel • techsupport@illumina.com • www.illumina.com

#### FOR RESEARCH USE ONLY


© 2012-2014 Illumina, Inc. All rights reserved.  
 Illumina, BaseSpace, MiSeq, TruSeq, the pumpkin orange color, and the Genetic Energy streaming bases design are trademarks or registered trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners.  
 Pub. No. 970-2012-014 Current as of 08 May 2014

**Table 2: Reproducibility of % Mutation**

Sample	1	2	3
Mutated Gene	KRAS	KRAS	BRAF
Expected % Mutation*	60%	40%	60%
% Mutation, Run 1 (Coverage)	57% (1767x)	37% (1948x)	60% (3902x)
% Mutation, Run 2 (Coverage)	55% (664x)	37% (656x)	59% (2616x)

\*Expected mutation rate estimated from Sanger sequencing chromatogram.

**Figure 2: Choosing Somatic Variant Caller Data Analysis**



To perform somatic variant caller data analysis, go to the Sample Sheet Wizard in the MiSeq Reporter's Illumina Experiment Manager and select it under Amplicon Workflow-Specific Settings (red box).

using the new somatic variant caller by simply re-editing the sample sheet to specify somatic variant calling. To download the latest version of MiSeq Reporter, please visit [www.illumina.com](http://www.illumina.com).

### Summary

The somatic variant caller is a powerful new tool for the analysis of cancer samples and can detect mutations below 5% frequency with high-quality sequencing from the MiSeq system and the TruSeq Amplicon - Cancer Panel.

### References

1. [www.illumina.com/Documents/products/datasheets/datasheet\\_truseq\\_amplicon\\_cancer\\_panel.pdf](http://www.illumina.com/Documents/products/datasheets/datasheet_truseq_amplicon_cancer_panel.pdf)
2. [www.illumina.com/Documents/products/other/review\\_cancer\\_research.pdf](http://www.illumina.com/Documents/products/other/review_cancer_research.pdf)
3. [www.illumina.com/documents/products/technotes/technote\\_eland\\_variantcalling\\_improvements.pdf](http://www.illumina.com/documents/products/technotes/technote_eland_variantcalling_improvements.pdf)